Zacks Investment Research downgraded shares of Fresenius Medical Care Corporation (NYSE:FMS) from a hold rating to a sell rating in a research report released on Tuesday.

According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company  ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”

Several other equities analysts have also recently weighed in on FMS. Nord/LB restated a buy rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. UBS AG restated a sell rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Royal Bank Of Canada restated a hold rating and set a $44.00 price target on shares of Fresenius Medical Care Corporation in a report on Wednesday, July 5th. BidaskClub cut Fresenius Medical Care Corporation from a strong-buy rating to a buy rating in a report on Monday, July 24th. Finally, DZ Bank AG restated a buy rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Fresenius Medical Care Corporation presently has an average rating of Hold and a consensus price target of $48.67.

Shares of Fresenius Medical Care Corporation (FMS) traded down 0.22% on Tuesday, hitting $48.94. The stock had a trading volume of 77,431 shares. The stock has a market capitalization of $30.04 billion, a P/E ratio of 21.00 and a beta of 0.48. Fresenius Medical Care Corporation has a 52 week low of $38.05 and a 52 week high of $50.22. The firm has a 50-day moving average price of $47.96 and a 200-day moving average price of $46.53.

Fresenius Medical Care Corporation (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.05). The firm had revenue of $4.47 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.96 EPS. Equities analysts expect that Fresenius Medical Care Corporation will post $2.34 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Fresenius Medical Care Corporation (FMS) Cut to Sell at Zacks Investment Research” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/06/fresenius-medical-care-corporation-fms-cut-to-sell-at-zacks-investment-research.html.

Several institutional investors have recently made changes to their positions in the company. Level Four Advisory Services LLC boosted its holdings in shares of Fresenius Medical Care Corporation by 0.5% in the 1st quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock worth $478,000 after purchasing an additional 58 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in shares of Fresenius Medical Care Corporation by 3.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after purchasing an additional 81 shares during the period. Greenleaf Trust boosted its holdings in shares of Fresenius Medical Care Corporation by 2.6% in the 2nd quarter. Greenleaf Trust now owns 4,992 shares of the company’s stock worth $241,000 after purchasing an additional 126 shares during the period. Sawtooth Solutions LLC boosted its holdings in shares of Fresenius Medical Care Corporation by 2.9% in the 2nd quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock worth $236,000 after purchasing an additional 137 shares during the period. Finally, Wrapmanager Inc. boosted its holdings in shares of Fresenius Medical Care Corporation by 2.4% in the 2nd quarter. Wrapmanager Inc. now owns 7,392 shares of the company’s stock worth $357,000 after purchasing an additional 170 shares during the period. Hedge funds and other institutional investors own 2.61% of the company’s stock.

About Fresenius Medical Care Corporation

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care Corporation (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.